Skip to main content

Advertisement

SpringerLink
Log in

Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

An Erratum to this article was published on 23 January 2007

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009–1022

    Article  PubMed  CAS  Google Scholar 

  2. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 78:2210–2215

    Article  PubMed  CAS  Google Scholar 

  3. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447–449

    PubMed  CAS  Google Scholar 

  4. Hanson RG, Peters MG, Hoofnagle JH (1986) Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 6:173–179

    Article  PubMed  CAS  Google Scholar 

  5. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM (2000) Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32:604–609

    Article  PubMed  CAS  Google Scholar 

  6. Chou CK, Wang LH, Lin HM, Chi CW (1992) Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16:13–18

    Article  PubMed  CAS  Google Scholar 

  7. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627–1631

    Article  PubMed  CAS  Google Scholar 

  8. Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ, Cheng AL (2004) Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24:3035–3040

    PubMed  CAS  Google Scholar 

  9. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188

    PubMed  CAS  Google Scholar 

  10. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307

    Article  PubMed  CAS  Google Scholar 

  11. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81:69–74

    Article  PubMed  CAS  Google Scholar 

  12. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561

    Article  PubMed  Google Scholar 

  13. Duhart BTJr., Honaker MR, Shokouh-Amiri MH, Riely CA, Vera SR, Taylor SL, Al-jedai AH, Gaber AO (2003) Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl Infect Dis 5:126–131

    Article  PubMed  Google Scholar 

  14. Locasciulli A, Bacigalupo A, Van Lint MT, et al. (1990) Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplant 6:25–29

    PubMed  CAS  Google Scholar 

  15. Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E, Aljurf M, Gyger M (2002) Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 30:189–194

    Article  PubMed  CAS  Google Scholar 

  16. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R (2002) Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100:391–396

    Article  PubMed  CAS  Google Scholar 

  17. Gane E, Pilmore H (2002) Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74:427–437

    Article  PubMed  CAS  Google Scholar 

  18. Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Seeff LB (1986) A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double–blind, placebo-controlled trial. Ann Intern Med 104:12–17

    PubMed  CAS  Google Scholar 

  19. Lam KC, Lai CL, Trepo C, Wu PC (1981) Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 304:380–386

    Article  PubMed  CAS  Google Scholar 

  20. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328

    Article  PubMed  CAS  Google Scholar 

  21. Chi ZC, Ma SZ (2003) Rheumatologic manifestations of hepatic diseases. Hepatobil Pancreat Dis Int 2:32–37

    Google Scholar 

  22. Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, Mizushima Y (1999) Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 28:273–281

    Article  PubMed  CAS  Google Scholar 

  23. Ahern MJ, Smith MD, Roberts-Thomson PJ (1998) Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 47:148–151

    Article  PubMed  CAS  Google Scholar 

  24. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M (2005) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25:472–489

    Article  PubMed  Google Scholar 

  25. Lok AS, McMahon BJ (2004) Chronic hepatitis B: update of recommendations. Hepatology 39:857–861

    Article  PubMed  Google Scholar 

  26. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749

    Article  PubMed  CAS  Google Scholar 

  27. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927–934

    Article  PubMed  CAS  Google Scholar 

  28. Liu CJ, Lai MY, Lee PH, Chou NK, Chu SH, Chen PJ, Kao JH, Jen YM, Chen DS (2001) Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 16:1001–1008

    Article  PubMed  CAS  Google Scholar 

  29. Conjeevaram HS, Lok AS (2003) Management of chronic hepatitis B. J Hepatol 38(Suppl 1):S90–103

    Article  PubMed  Google Scholar 

  30. Liaw YF, Chien RN (1999) Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B. J Gastroenterol Hepatol 14:804–806

    Article  PubMed  CAS  Google Scholar 

  31. Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, Kuhns MC (1988) Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 109:95–100

    PubMed  CAS  Google Scholar 

  32. Tupasi TE, Co VM, Clarin MS, Alesna ET, Divinagracia EM, Mangubat NV (2002) Randomized, double-blind, placebo-controlled trial of oromucosal low-dose interferon following prednisone withdrawal for chronic hepatitis B infection in Filipino patients. Int J Infect Dis 6:37–41

    Article  PubMed  Google Scholar 

  33. Liaw YF (1997) Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 12:S346–S353

    Article  PubMed  CAS  Google Scholar 

  34. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS (1983) Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 84:216–219

    PubMed  CAS  Google Scholar 

  35. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W (2005) Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV Core antigen: low risk of HBV reactivation. Transplantation 79:1631–1633

    Article  PubMed  Google Scholar 

  36. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311

    Article  PubMed  CAS  Google Scholar 

  37. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R (2002) High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324–2330

    Article  PubMed  CAS  Google Scholar 

  38. Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ (2004) High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11:55–59

    Article  PubMed  CAS  Google Scholar 

  39. Vento S, Cainelli F, Longhi MS (2002) Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 3:333–340

    Article  PubMed  CAS  Google Scholar 

  40. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473–477

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by grants from the Liver Disease Prevention & Treatment Research Foundation, Taiwan.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei, Taiwan, 100

    Feng-Chiao Tsai, Song-Chou Hsieh, Ding-Shinn Chen, Jin-Chuan Sheu & Ding-Shinn Chen

  2. Hepatitis Research Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

    Ding-Shinn Chen

Authors
  1. Feng-Chiao Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Song-Chou Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ding-Shinn Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin-Chuan Sheu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ding-Shinn Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ding-Shinn Chen.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10620-006-9609-z

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsai, FC., Hsieh, SC., Chen, DS. et al. Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents. Dig Dis Sci 51, 1627–1632 (2006). https://doi.org/10.1007/s10620-006-9074-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9074-8

Keywords

Search

Navigation